Abstract: The present disclosure includes methods, apparatuses, and systems for three-dimensional phenotyping and physiologic characterization of brain lesions and tissue encompassing one or more enlarged boundaries surrounding the brain lesion to study the metabolic and physiologic profiles from tissue within and around lesions and their impacts on lesion shape and surface texture. The non-invasive biomarker blood-oxygen their impacts on lesion shape and surface texture. The non-invasive biomarker blood-oxygen-level-dependant (BOLD) slope was used to metabolically characterize lesions. Metabolically active lesions with more intact tissue and myelin architecture have more symmetrical shapes and more complex surface textures compared to metabolically inactive lesions with less intact tissue and myelin architecture.

Abstract: Modular dendrimers with cationic groups and lipophilic groups are provided herein. In some aspects, the dendrimers provided herein may be formulated in compositions which contain a nucleic acid and one or more helper excipients. In some aspects, these compositions may also be used to treat diseases or disorders with a therapeutic nucleic acid.

Abstract: A motor-deficit-therapeutic method (for treatment of a patient who has hemiparesis) includes: providing, to the patient afflicted with a hemiparesis, a neurostimulator configured to stimulate a vagus nerve of the patient using electrical, magnetic, optical, acoustic or mechanical stimulation; and initiating stimulation of the vagus nerve by the neurostimulator so that at least a portion of the stimulation occurs at least during performance by the patient of a motor therapy session which is hemiparesis-therapeutic, thereby improving the patient's hemiparesis.

Abstract: Devices and methods for nasal administration of a pharmaceutical composition. In certain embodiments, the devices comprises a reservoir, a conduit in fluid communication with the reservoir, and an anatomic positioning device configured to position the conduit in a nasal cavity of a user. Particular embodiments include an actuator configured to transfer the pharmaceutical composition from the reservoir to the conduit and emit the pharmaceutical composition from the conduit.

Abstract: Isolated or recombinant anti-EGFL6 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.

Abstract: Provided herein are anti-CD5L monoclonal antibodies. Further provided herein are methods of use thereof for the treatment of a disease or disorder, such as cancer.

Abstract: Aspects of the present disclosure are directed to methods for treating a subject having cancer. Certain aspects relate to treating a subject for lung cancer by administering a kinase inhibitor to a subject determined, from analysis of tumor DNA from the subject, to have an EGFR mutation of a particular classification. Further aspects relate to methods for treating a subject for lung cancer by detecting an EGFR mutation of a particular classification in tumor DNA from the subject and administering an effective amount of a kinase inhibitor to the subject. Also disclosed are methods for stratifying and prognosing subjects based on EGFR mutation classification.

Abstract: Aspects of the present disclosure are directed to immune cells comprising polynucleotides encoding genetically engineered receptors (e.g., chimeric antigen receptors, T-cell receptors) and having anti-CD20 antibodies (or fragments thereof) attached to their surface. Certain aspects are directed to preactivated and/or expanded natural killer cells having anti-CD20 antibodies (or fragments thereof) attached to their surface. Also disclosed are compositions comprising such cells, and methods for using such compositions to treat an individual having CD20-positive cancer. Further aspects encompass methods for cell preparation comprising culturing natural killer cells with cytokines (e.g., IL-12, IL-15, and/or IL-18) and incubating the cells with an anti-CD20 antibody.

Abstract: Total energy shaping control methods and devices for powered orthosis for controlling the device to counteract forces exerted on the person including inertial forces.

Abstract: Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.

Abstract: The present disclosure describes apparatuses and methods related to suture anchors. One such apparatus involves an inserter instrument for a suture anchor implant comprising a handle; a hollow outer barrel shaft extending from one end of the inserter instrument to an opposing end at an anchor screw attachment tip; and an inner barrel shaft extending along a length of the inserter instrument within a cavity of the hollow outer barrel shaft. The inserter instrument further includes a tension sensor coupled to an end of the inner barrel shaft, which can measure an amount of tension applied to an opposing end of the inner barrel shaft and output an electrical signal indicating a value of the measured tension, such that an electronic display communicatively coupled to the tension sensor can display the value of the measured tension indicated by the electrical signal.

Abstract: In one embodiment, a needle guide includes a guide element including a hollow body having a first opening at a first end, a second opening at a second end, and an interior space defined by an inner wall of the body that extends from the first opening to the second opening, wherein the second opening is smaller than the first opening and is configured to receive a needle having a tip that is to be positioned within a target site of a patient, and wherein the body includes a radiopaque material at the second opening that can be viewed during real-time medical imaging to facilitate placement and insertion of the needle.

Abstract: Provide herein are polynucleotides comprising a codon-optimized AP4M1 open reading frame (ORF) sequence encoding an AP4M1 polypeptide, vectors (viral or non-viral vectors) comprising the same, pharmaceutical compositions comprising the same, and methods of using the same for delivery of the polynucleotides to a cell or a subject and to treat AP4M1-related genetic disorders such as AP4M1 deficiency and spastic paraplegia type 50.

Abstract: The present disclosure provides methods and compositions for the treatment of diseases and genetic disorders linked to SLC6A1 loss and/or misfunction. The methods and compositions of the present disclosure comprise rAAV vectors and rAAV viral vectors comprising transgene nucleic acid molecules comprising nucleic acid sequences encoding for a GAT1 polypeptide.

Abstract: Compositions and methods for treatment of one or more metabolic disorders in a subject are provided. Disclosures herein are directed to compositions comprising a beta-adrenergic receptor (ADRB1) antagonist and a beta-3 adrenergic receptor (ADRB3) agonist and methods of using such compositions for treating, preventing, and/or ameliorating a metabolic disease or a metabolic disease condition.

Abstract: Provided herein are engineered hMPV F proteins. In some aspects, the engineered F proteins exhibit enhanced conformational stability and/or antigenicity. Methods are also provided for use of the engineered F proteins as diagnostics, in screening platforms, and/or in vaccine compositions.

Abstract: Immunogenic compositions comprising viral vectors and surfactants are provided. Methods for administration and preparation of such compositions are also provided.

Abstract: The present disclosure provides methods and compositions for treatment of KRAS mutant cancer. Aspects of the disclosure are directed to methods for treatment of KRAS mutant cancer, including KRAS mutant non-small cell lung cancer, comprising administering a KRAS inhibitor (e.g., sotorasib, adagrasib) and poziotinib. Also disclosed are pharmaceutical compositions comprising a KRAS inhibitor (e.g., sotorasib, adagrasib) and poziotinib.

Abstract: In one embodiment, a wheelchair device includes a frame adapted to be removably mounted to a wheelchair, a slide member supported by the frame that is configured to be pushed in a forward direction away from a user of the device with the user's arm, a transmission mechanism including a rotatable reel and a spring associated with the reel that resists rotation of the reel in a first direction and assists rotation of the reel in a second direction, and a cable having first and second ends, the first end of the cable being attached to the slide member and the second end being attached to the rotatable reel. With such a configuration, movement of the slide member in the forward direction causes the rotatable reel to rotate in the first direction and movement of the slide member in a backward direction opposite to the forward direction causes the rotatable reel to rotate in the second direction.

Abstract: The present disclosure is directed towards a treatment planning system for use in a stereotactic radiotherapy system. In particular, the disclosed systems and methods may be used for generating a treatment plan and/or verifying an existing treatment plan. Moreover, the disclosed systems and methods may be suitable for use in a clinical setting. A method for verifying a treatment plan of a stereotactic radiotherapy device may include the steps of receiving a treatment plan, generating a second treatment plan by applying a modified monte-carlo method to regions of interest in the treatment plan, and identifying discrepancies between the received treatment plan and the generated second treatment plan.